Kymera Investor Presentation Deck

Durable Anti-Tumor Activity of STAT3 Degradation as a Single Agent in Preclinical Models of T cell Lymphoma Tumor Volume (mm³) +SEM Mean, 100000 KT-333 Concentration (ng/ml or ng/g) 10000 1000 100 10 3000 1 2000 1000 0 Complete Tumor Regressions Associated with >90% STAT3 KD for ~48h Achieved with Intermittent Dosing of KT-333 Vehicle KT-333, 5 mg/kg, QW KT-333, 10 mg/kg, QW 0 5 15 Days (Post-randomization) 10 48 20 Tumor PK Plasma PK → Tumor PD 192 25 240 96 144 Time (hr) KYMERA ©2023 KYMERA THERAPEUTICS, INC. 100 150 in vivo PD 50 ALK+ ALCL 0 SU-DHL-1 % of Vehicle Control STAT3 MFI Disease Severity Score* + N 15000 10000 5000- 0 Vehicle (n=3) KTX-115 30 mpk, QW 4-weeks ON/1-week OFF (n=4) 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 Duration of Treatment (Weeks) Vehicle (n=3) KTX-115, 30 mpk, QW x 3 (n=3) STAT3 Degradation Results in Disease Amelioration in a CTCL Preclinical Model with Potent Degradation of STAT3 in CD4+ T Cell-of-Origin Circulating CD4 T Cells wt Stat3Cstopfl/+ CD4Cre STAT3 MFI in vivo PD Lymph Node CD4 T Cells 15000 ||||||| 10000 5000 0 wt Stat3Cstopfl/+ CD4Cre CTCL GEMM Fanok et al. (2018) Collaboration with NYU STAT3 MFI 25000 20000 15000 10000- 64th ASHⓇ Annual Meeting and Exposition 0 Skin CD4 T Cells 5000 O wt 8 Stat3Cstopfl/+ CD4Cre PAGE 23

View entire presentation